Business Wire

GRAVITY-INTERACTIVE

22.8.2019 17:48:03 CEST | Business Wire | Press release

Share
Gravity Unveils its Future Plans During Gamescom 2019

Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd . (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany from August 20th to 24th .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005507/en/

On August 20th , Gravity held a presentation in the Korea Pavilion. In front of various global game companies and media outlets, it announced its plans to launch ‘Ragnarok M: Eternal Love’ in the European region.

During the presentation, Gravity spoke about the huge international success of ‘Ragnarok M: Eternal Love’, its plans to launch the European service for the game, and the direction that the local service will take.

The Company also spoke about the re-launching of ‘Ragnarok Online’ by the new publisher, Innova, with its release planned for September 4th 2019. A CBT (Closed Beta Test) period will take place before the official relaunch.

During the presentation, Yoshinori Kitamura, CEO of Gravity Interactive, Inc. said he is delighted regarding ‘Ragnarok M: Eternal Love’s launch in Russia, Turkey, as well as Europe and explained it will be serviced in seven languages including English, Portuguese, Spanish, Russian, German, French, and Turkish.

Yoshinori Kitamura also mentioned that he hopes that the re-launching of ‘Ragnarok Online’ by Innova in Europe will contribute to spreading the value of the Ragnarok brand. As Europe is the third largest game market in the world, Gravity realizes its importance. He also added that through its expertise Gravity will provide the best service to European users.

‘Ragnarok M: Eternal Love’ was first launched in 2017 in China, Taiwan, Hong Kong and Macau. Then in 2018 it was launched in South Korea and South East Asia. In 2019, the game was launched in North and South America. Since March 2019, the game has been downloaded over 24 million times and has been a huge hit. ‘Ragnarok Online’ is currently available in over 70 countries.

Pre-register Page for ‘Ragnarok M: Eternal Love’: https://romeleu.com

Link:

ClickThru

Social Media:

https://www.facebook.com/PlayRagnarokMEU

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 06:00:00 CEST | Press release

Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye